Morningstar

Inovio Gets Accelerated FDA Approval of Voceryq; Shares More Than Triple After Hours

Provided by Dow Jones Oct 30, 2026, 10:38:00 PM

By Josh Beckerman

Inovio Pharmaceuticals said the Food and Drug Administration granted accelerated approval of Voceryq to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis.

Shares more than tripled after hours to $2.17.

The drug was previously known as INO-3107.

Inovio expects Voceryq will be available to order and ship in about 60 days, with full commercial launch in the first quarter of 2027.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 30, 2026 18:38 ET (22:38 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

5 Stocks to Buy Trading at Big Discounts

Plus, what recent bond market volatility means for investors.

David Sekera, CFA and Sarah Hansen Oct 26, 2026

This Once-Hot AI Stock Now Looks Deeply Undervalued

This chip stock looks cheap at a 30% discount, and its biggest growth years could still be ahead.

William Kerwin, CFA Oct 29, 2026

2 Undervalued Stocks to Buy With Long-Term Growth Ahead

Defense spending and booming data center demand could provide powerful tailwinds for these 4-star stocks.

David Sekera, CFA, Sarah Hansen, and Jess Bebel Oct 23, 2026

What 7 Key Market Indicators Are Telling Investors Right Now

US equity valuations have retreated from their recent highs, but all 7 major market indicators remain above their long-term averages.

Amy C. Arnott, CFA Oct 27, 2026

Don’t Overlook the Income Side of Fixed Income

Amid bond market tumult, elevated yields are contributing to returns and offering investors a nice income stream.

Dan Lefkovitz Oct 28, 2026

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.